Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shinhung Co., Ltd (004080.KS)
Seoul, KR
Operating primarily in South Korea, Shinhung Co., Ltd. specializes in the production and distribution of a comprehensive array of dental goods and supplies. Their extensive product line features sophisticated implant systems and related components, essential clinical setups including dental units, chairs, and operatories, as well as critical sterilization and diagnostic equipment such as autoclaves and X-ray machines. They also provide disposable needles and various laboratory provisions like dental porcelain powders and alloys. Furthermore, the company offers a range of specialized cabinetry, encompassing drawer, equipment, sink, and mobile units, alongside other vital apparatus like compressors and mixers. Beyond its manufacturing and sales activities, Shinhung extends financial assistance to dental professionals through loan services. Established in 1955, the company's main operations are directed from its headquarters in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -1.09% | -2.09% | -2.65% | +0.67% | -2.86% | -6.85% | -4.09% | -6.21% | +17.24% | +172.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+0.8% Q1'26: +6.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-43.6% Q1'26: +176.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-7.1% Q1'26: -20.1% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+6.9% ★ Q1'26: +3.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+3.4% ★ Q1'26: +1.8% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-3.9% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.59× Q1'26: 2.47× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-15 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ki-Hwan Choi | Senior Managing Director and Director | — | — |
| Yeung-Kyu Lee | Founder and Chairman | — | male |
| Yong-Hun Lee | Managing Director and Director | — | — |
| Yong-Ik Yi | Chief Executive Officer, President and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 004080.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
